Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ISRG News 23 January 2026 - 4 February 2026

Intuitive Surgical stock price steadies near $480 as ISRG weathers Wall Street jitters

Intuitive Surgical stock price steadies near $480 as ISRG weathers Wall Street jitters

Intuitive Surgical shares rose 0.2% to $480.02 Wednesday afternoon after a volatile session, rebounding slightly from a two-day slide. The Nasdaq-tracking QQQ fell 1.6%, while the iShares U.S. Medical Devices ETF dropped 1%. Medtronic declined as Stryker gained. Trading volume in Intuitive surged to 3.8 million shares, more than double its 50-day average.
4 February 2026
····
Intuitive Surgical stock slips into the weekend: ISRG traders eye insider sale, tariffs, and what comes next

Intuitive Surgical stock slips into the weekend: ISRG traders eye insider sale, tariffs, and what comes next

Intuitive Surgical shares fell 0.7% to $504.22 Friday after a filing showed Chief Medical Officer Myriam Curet sold 126 shares under a 10b5-1 plan. The stock traded between $501.44 and $510.75 on volume of 1.7 million. Investors are watching for signs of procedure growth and tariff impacts ahead of quarterly earnings.
1 February 2026
·····
Intuitive Surgical stock (ISRG) ends week lower as insider trades surface; what to watch next

Intuitive Surgical stock (ISRG) ends week lower as insider trades surface; what to watch next

Intuitive Surgical shares fell 0.66% to $504.22 Friday, extending a two-day slide after a 2.78% drop Thursday. EVP Myriam Curet sold 126 shares at $520.02 each under a preset plan, while CEO David Rosa received performance stock units set to vest in 2026 and 2027. The company forecasts 2026 procedure growth of 13%-15% and a 67%-68% non-GAAP gross margin, factoring in a 1.2% tariff hit. Markets reopen Monday.
1 February 2026
·····
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
······
Intuitive Surgical stock in focus after FDA clears da Vinci 5 for heart procedures

Intuitive Surgical stock in focus after FDA clears da Vinci 5 for heart procedures

Intuitive Surgical shares rose nearly 1% to $528.81 after U.S. regulators cleared its da Vinci 5 system for select cardiac procedures. The FDA approval covers thoracoscopic cardiac surgeries using non-force feedback tools. TD Cowen started coverage with a Buy rating and a $660 price target. About 17,000 da Vinci cardiac procedures were performed globally in 2025.
27 January 2026
···
ISRG stock edges up after Intuitive Surgical wins FDA clearance for da Vinci 5 heart procedures

ISRG stock edges up after Intuitive Surgical wins FDA clearance for da Vinci 5 heart procedures

Intuitive Surgical shares rose about 1% after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The company plans a limited U.S. rollout through 2026. The clearance follows last week’s warning of slower global procedure growth, with forecasts now at 13% to 15% for 2026. Investors are weighing the new approval against concerns over hospital budgets and rising competition.
26 January 2026
····
Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

Intuitive Surgical shares closed at $523.99 Friday, down 0.4% after the company forecast da Vinci procedure growth of 13%–15% by 2026 and warned tariffs could pressure margins. Fourth-quarter revenue rose 19% to $2.87 billion, with adjusted earnings of $2.53 per share. The company reported over 20 million da Vinci procedures worldwide. FDA cleared new cardiac uses for its da Vinci 5 robot.
25 January 2026
·····
Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus

Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus

Intuitive Surgical shares closed Friday at $523.99, down 0.4%, after the company beat quarterly estimates but projected slower da Vinci procedure growth and flagged higher tariff costs for 2026. The firm reported Q4 revenue of $2.87 billion and installed 532 da Vinci systems. U.S. markets remain closed until Monday. Investors focused on tariffs and hospital demand signals heading into next week.
25 January 2026
·····
Intuitive Surgical stock slips as 2026 growth outlook cools — what to watch before Monday

Intuitive Surgical stock slips as 2026 growth outlook cools — what to watch before Monday

Intuitive Surgical shares fell 0.35% to $523.99 Friday after the company forecast 13%-15% procedure growth for 2026 and warned tariffs could cut margins by 1.2% of revenue. Fourth-quarter revenue rose 19% to $2.87 billion, with da Vinci 5 placements up but Ion placements down. The FDA cleared da Vinci 5 for select cardiac procedures this week.
24 January 2026
·····
Intuitive Surgical stock price dips as 2026 da Vinci outlook cools after Q4 beat (ISRG)

Intuitive Surgical stock price dips as 2026 da Vinci outlook cools after Q4 beat (ISRG)

Intuitive Surgical shares fell 0.2% to $524.65 after the company forecast slower da Vinci procedure growth of 13–15% for 2026, down from 18% in 2025. Fourth-quarter revenue rose 19% to $2.87 billion, with adjusted profit topping estimates. Management cited tariff risks and rising competition as headwinds. The company installed 532 da Vinci systems in Q4, bringing its total to 11,106.
23 January 2026
·····
Intuitive Surgical stock jumps premarket after earnings beat, but 2026 tariff hit gets attention

Intuitive Surgical stock jumps premarket after earnings beat, but 2026 tariff hit gets attention

Intuitive Surgical shares jumped 3.6% premarket to $545 after beating fourth-quarter estimates and reporting an 18% rise in global procedures. The company forecast slower 2026 procedure growth of 13%–15% and said tariffs would cut margins by about 1.2% of revenue. Traders are watching for analyst updates at the open. Cash and investments totaled $9.03 billion at year-end.
23 January 2026
····
Intuitive Surgical stock whipsaws after Q4 beat as 2026 da Vinci outlook and tariffs hit focus

Intuitive Surgical stock whipsaws after Q4 beat as 2026 da Vinci outlook and tariffs hit focus

Intuitive Surgical shares rose 0.4% to $525.81 in after-hours trading Thursday after quarterly earnings beat forecasts. The company reported a 19% revenue increase to $2.87 billion, with da Vinci procedures up 17%. Intuitive projects 13%-15% da Vinci procedure growth in 2026 but warned tariffs could cut margins. Investors remain focused on procedure growth and tariff impacts ahead of Friday’s session.
23 January 2026
·····
1 2 3 4

Stock Market Today

Westpac share price slides after ASX rout; investors brace for next week’s WBC update

Westpac share price slides after ASX rout; investors brace for next week’s WBC update

7 February 2026
Westpac shares fell 1.2% to A$39.43 Friday as the S&P/ASX 200 dropped 2% amid broad selling. The bank is set to roll out Microsoft 365 Copilot to 35,000 staff after a pilot last year. Investors are watching for signs of loan growth and credit quality ahead of Westpac’s first-quarter update on Feb. 13. The Reserve Bank of Australia raised its cash rate to 3.85% this week.
ANZ share price fell Friday — here’s what to watch before the ASX reopens

ANZ share price fell Friday — here’s what to watch before the ASX reopens

7 February 2026
ANZ shares closed at A$37.01 on Friday, down 1.52% as the S&P/ASX 200 fell 2% and nearly $70 billion was wiped from the market. The Reserve Bank of Australia raised its cash rate by 0.25 points to 3.85%, prompting ANZ to lift variable home loan rates from Feb. 13. ANZ announced a new Salesforce-based AI CRM rollout and a board change effective Feb. 8. Investors await ANZ’s first-quarter update on Feb. 12.
Go toTop